EffRx Pharmaceuticals SA is a commercial-stage pharmaceutical company, based in Switzerland, that develops and commercializes prescription medications for specialty indications. The primary focus is on therapeutics for men and women with musculoskeletal and genitourinary disorders. The business model is centered around providing superior clinical and commercial value propositions for physicians, payers and patients. We address real, unmet medical needs and strive to improve patient outcomes.
Location: Switzerland, Schwyz, Wilen
Employees: 11-50
Phone: +41 44 503 78 60
Total raised: $10.28M
Founded date: 1998
Investors 1
| Date | Name | Website |
| - | Midroc New... | midroc.se |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 13.01.2015 | - | $2.3M | - |
| 01.10.2013 | Grant | $7.98M | - |
Mentions in press and media 9
| Date | Title | Description |
| 08.09.2023 | World Orphan Drug Alliance Welcomes Specialised Therapeutics | SEA's largest independent specialty pharma company Specialised Therapeutics (ST) has joined global pharma consortium committed to collaborating to provide new specialist medicines for rare diseases. ST to represent WODA in Australia, New Ze... |
| 30.05.2023 | EffRx Pharmaceuticals SA exits to Italy’s Abiogen Pharma | |
| 29.05.2023 | Abiogen Pharma Acquires 97,09% Stake in EffRx Pharmaceuticals | Abiogen Pharma, a Pisa, Italy-based company focused on osteoarticular and bone metabolism diseases, acquired a 97,09% stake in EffRx Pharmaceuticals, a Freienbach, Switzerland-based company that develops and markets prescription drugs targe... |
| 16.11.2021 | IP : Diurnal Group plc - Alkindi® approved by Swissmedic for use in Switzerland | Market launch by EffRx Pharmaceuticals expected during H1 2022 to address unmet need in paediatric AI Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, annou... |
| 16.11.2021 | Diurnal : Alkindi® approved by Swissmedic for use in Switzerland | Market launch by EffRx Pharmaceuticals expected during H1 2022 to address unmet need in paediatric AI Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, annou... |
| 17.04.2015 | Nine hot start-ups, 400 visitors and Joe Jimenez | |
| 26.01.2015 | EffRx – The next Swiss IPO candidate | |
| 13.01.2015 | EffRx Pharmaceuticals Raises over CHF2.3M in Equity Funding | EffRx Pharmaceuticals SA, a Freienbach, Switzerland-based specialty pharmaceutical company, raised over CHF2.3m in equity funding. All funds were raised through existing shareholders. The company intends to use the funds to launch its first... |
| 27.09.2007 | Life sciences briefing: Thursday, Sept. 27, 2007 | Featured companies: AstraZeneca, Atlantis Components, Cara Therapeutics, CardioMems, Corium International, New Ortho Polymers, Osprey Pharmaceuticals, Othera Pharmaceuticals, StrataGent Life Sciences Corium acquires Stratagent, raises $25.1... |